{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:48:58Z","timestamp":1782226138769,"version":"3.54.5"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40256-025-00732-1","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T07:20:52Z","timestamp":1745047252000},"page":"577-592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Appraisal of \u03b2-Blocker Use in Patients with Cardiovascular Disease and Chronic Obstructive Pulmonary Disease"],"prefix":"10.1007","volume":"25","author":[{"given":"Ruicong","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"key":"732_CR1","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/01.CIR.0000065187.80707.18","volume":"107","author":"M Gheorghiade","year":"2003","unstructured":"Gheorghiade M, Colucci WS, Swedberg K. \u03b2-blockers in chronic heart failure. Circulation. 2003;107:1570\u20135. https:\/\/doi.org\/10.1161\/01.CIR.0000065187.80707.18.","journal-title":"Circulation"},{"key":"732_CR2","unstructured":"Morris J, Awosika AO, Dunham A. Metoprolol. [Updated 2023 Aug 29]. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532923\/."},{"key":"732_CR3","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.2147\/COPD.S438930","volume":"18","author":"Z Feng","year":"2023","unstructured":"Feng Z, Zhang L, Wang Y, Guo H, Liu J. Efficacy and safety of bisoprolol in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2023;18:3067\u201383. https:\/\/doi.org\/10.2147\/COPD.S438930.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"732_CR4","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s10557-021-07205-y","volume":"36","author":"W AlHabeeb","year":"2022","unstructured":"AlHabeeb W, Mrabeti S, Abdelsalam AAI. Therapeutic properties of highly selective \u03b2-blockers with or without additional vasodilator properties: focus on bisoprolol and nebivolol in patients with cardiovascular disease. Cardiovasc Drugs Ther. 2022;36:959\u201371. https:\/\/doi.org\/10.1007\/s10557-021-07205-y.","journal-title":"Cardiovasc Drugs Ther"},{"key":"732_CR5","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2217\/fca-2021-0048","volume":"17","author":"C Ferri","year":"2021","unstructured":"Ferri C. The role of nebivolol in the management of hypertensive patients: from pharmacological profile to treatment guidelines. Future Cardiol. 2021;17:1421\u201333. https:\/\/doi.org\/10.2217\/fca-2021-0048.","journal-title":"Future Cardiol"},{"key":"732_CR6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/bcpt.13248","volume":"125","author":"N Olawi","year":"2019","unstructured":"Olawi N, Kr\u00fcger M, Grimm D, Infanger M, Wehland M. Nebivolol in the treatment of arterial hypertension. Basic Clin Pharmacol Toxicol. 2019;125:189\u2013201. https:\/\/doi.org\/10.1111\/bcpt.13248.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"732_CR7","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s40265-018-0999-y","volume":"78","author":"AFG Cicero","year":"2018","unstructured":"Cicero AFG, Kuwabara M, Borghi C. A critical review of nebivolol and its fixed-dose combinations in the treatment of hypertension. Drugs. 2018;78:1783\u201390. https:\/\/doi.org\/10.1007\/s40265-018-0999-y.","journal-title":"Drugs"},{"key":"732_CR8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2165\/00003495-199345020-00006","volume":"45","author":"D McTavish","year":"1993","unstructured":"McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1993;45:232\u201358. https:\/\/doi.org\/10.2165\/00003495-199345020-00006.","journal-title":"Drugs"},{"key":"732_CR9","unstructured":"Agarwal AK, Raja A, Brown BD. Chronic obstructive pulmonary disease. [Updated 2023 Aug 7]. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559281\/."},{"key":"732_CR10","doi-asserted-by":"publisher","first-page":"2202364","DOI":"10.1183\/13993003.02364-2022","volume":"62","author":"LC Maclagan","year":"2023","unstructured":"Maclagan LC, Croxford R, Chu A, Sin DD, Udell JA, Lee DS, et al. Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort. Eur Respir J. 2023;62:2202364. https:\/\/doi.org\/10.1183\/13993003.02364-2022.","journal-title":"Eur Respir J"},{"key":"732_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12890-023-02606-1","volume":"23","author":"H Chen","year":"2023","unstructured":"Chen H, Luo X, Du Y, He C, Lu Y, Shi Z, et al. Association between chronic obstructive pulmonary disease and cardiovascular disease in adults aged 40 years and above: data from NHANES 2013\u20132018. BMC Pulm Med. 2023;23:318. https:\/\/doi.org\/10.1186\/s12890-023-02606-1.","journal-title":"BMC Pulm Med"},{"key":"732_CR12","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1164\/rccm.201604-0690SO","volume":"194","author":"S Roversi","year":"2016","unstructured":"Roversi S, Fabbri LM, Sin DD, Hawkins NM, Agust\u00ed A. Chronic obstructive pulmonary disease and cardiac diseases: an urgent need for integrated care. Am J Respir Crit Care Med. 2016;194:1319\u201336. https:\/\/doi.org\/10.1164\/rccm.201604-0690SO.","journal-title":"Am J Respir Crit Care Med"},{"key":"732_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-2600(15)00241-6","volume":"3","author":"W Chen","year":"2015","unstructured":"Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3:631\u20139. https:\/\/doi.org\/10.1016\/S2213-2600(15)00241-6.","journal-title":"Lancet Respir Med"},{"key":"732_CR14","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1378\/chest.12-2847","volume":"144","author":"H M\u00fcllerova","year":"2013","unstructured":"M\u00fcllerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144:1163\u201378. https:\/\/doi.org\/10.1378\/chest.12-2847.","journal-title":"Chest"},{"key":"732_CR15","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1001\/jama.1994.03520190043033","volume":"272","author":"NR Anthonisen","year":"1994","unstructured":"Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272:1497\u2013505.","journal-title":"JAMA"},{"key":"732_CR16","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1378\/chest.128.4.2068","volume":"128","author":"S Sidney","year":"2005","unstructured":"Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005;128:2068\u201375. https:\/\/doi.org\/10.1378\/chest.128.4.2068.","journal-title":"Chest"},{"key":"732_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2147\/JEP.S259328","volume":"12","author":"RM Burkes","year":"2020","unstructured":"Burkes RM, Panos RJ. Ultra long-acting \u03b2-agonists in chronic obstructive pulmonary disease. J Exp Pharmacol. 2020;12:589\u2013602. https:\/\/doi.org\/10.2147\/JEP.S259328.","journal-title":"J Exp Pharmacol"},{"key":"732_CR18","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1136\/thoraxjnl-2019-214206","volume":"75","author":"DB Rasmussen","year":"2020","unstructured":"Rasmussen DB, Bodtger U, Lamberts M, Torp-Pedersen C, Gislason G, Lange P, et al. Beta-blocker use and acute exacerbations of COPD following myocardial infarction: a Danish nationwide cohort study. Thorax. 2020;75:928\u201333. https:\/\/doi.org\/10.1136\/thoraxjnl-2019-214206.","journal-title":"Thorax"},{"key":"732_CR19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/17476348.2020.1752671","volume":"14","author":"C Wade","year":"2020","unstructured":"Wade C, Wells JM. Practical recommendations for the use of beta-blockers in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2020;14:671\u2013867. https:\/\/doi.org\/10.1080\/17476348.2020.1752671.","journal-title":"Expert Rev Respir Med"},{"key":"732_CR20","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1136\/heartjnl-2016-309458","volume":"102","author":"B Lipworth","year":"2016","unstructured":"Lipworth B, Skinner D, Devereux G, Thomas V, Ling Zhi Jie J, Martin J, et al. Underuse of \u03b2-blockers in heart failure and chronic obstructive pulmonary disease. Heart. 2016;102:1909\u201314. https:\/\/doi.org\/10.1136\/heartjnl-2016-309458.","journal-title":"Heart"},{"key":"732_CR21","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1056\/NEJMoa1908142","volume":"381","author":"MT Dransfield","year":"2019","unstructured":"Dransfield MT, Voelker H, Bhatt SP, Brenner K, Casaburi R, Come CE, et al. Metoprolol for the prevention of acute exacerbations of COPD. N Engl J Med. 2019;381:2304\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1908142.","journal-title":"N Engl J Med"},{"key":"732_CR22","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1513\/AnnalsATS.202109-1042OC","volume":"19","author":"TM Parekh","year":"2022","unstructured":"Parekh TM, Helgeson ES, Connett J, Voelker H, Ling SX, Lazarus SC, et al. Lung function and the risk of exacerbation in the \u03b2-blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease trial. Ann Am Thorac Soc. 2022;19:1642\u20139. https:\/\/doi.org\/10.1513\/AnnalsATS.202109-1042OC.","journal-title":"Ann Am Thorac Soc"},{"key":"732_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.7326\/0003-4819-137-9-200211050-00035","volume":"137","author":"SR Salpeter","year":"2002","unstructured":"Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective \u03b2-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137:715\u201325. https:\/\/doi.org\/10.7326\/0003-4819-137-9-200211050-00035.","journal-title":"Ann Intern Med"},{"key":"732_CR24","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.jacc.2010.01.024","volume":"55","author":"A Jabbour","year":"2010","unstructured":"Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55:1780\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2010.01.024.","journal-title":"J Am Coll Cardiol"},{"key":"732_CR25","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1183\/09031936.00153707","volume":"31","author":"Y Ling","year":"2008","unstructured":"Ling Y, Saleem W, Shee D. Concomitant use of \u03b2-blockers and \u03b22-agonists. Eur Respir J. 2008;31:905\u20136. https:\/\/doi.org\/10.1183\/09031936.00153707.","journal-title":"Eur Respir J"},{"key":"732_CR26","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1002\/ehf2.14497","volume":"10","author":"NM Hawkins","year":"2023","unstructured":"Hawkins NM, Peterson S, Salimian S, Demers C, Keshavjee K, Virani SA, et al. Epidemiology and treatment of heart failure with chronic obstructive pulmonary disease in Canadian primary care. ESC Heart Fail. 2023;10:3612\u201321. https:\/\/doi.org\/10.1002\/ehf2.14497.","journal-title":"ESC Heart Fail."},{"key":"732_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/ehjqcco\/qcy063","volume":"6","author":"DB Rasmussen","year":"2020","unstructured":"Rasmussen DB, Bodtger U, Lamberts M, Nicolaisen SK, Sessa M, Capuano A, et al. Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. Eur Heart J Qual Care Clin Outcomes. 2020;6:23\u201331. https:\/\/doi.org\/10.1093\/ehjqcco\/qcy063.","journal-title":"Eur Heart J Qual Care Clin Outcomes."},{"key":"732_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab724.0289","author":"CS Benson","year":"2021","unstructured":"Benson CS, Dalgaard F, Rasmussen PV, Hansen ML, Lamberts M, Ruwald MH, et al. Beta-blocker treatment in atrial fibrillation with chronic obstructive pulmonary disease: a Danish nationwide study from 1995 to 2015. Eur Heart J. 2021. https:\/\/doi.org\/10.1093\/eurheartj\/ehab724.0289.","journal-title":"Eur Heart J"},{"key":"732_CR29","doi-asserted-by":"publisher","first-page":"euae021","DOI":"10.1093\/europace\/euae021","volume":"26","author":"GF Romiti","year":"2023","unstructured":"Romiti GF, Corica B, Mei DA, Frost F, Bisson A, Boriani G, et al. Impact of chronic obstructive pulmonary disease in patients with atrial fibrillation: an analysis from the GLORIA-AF registry. Europace. 2023;26:euae021. https:\/\/doi.org\/10.1093\/europace\/euae021.","journal-title":"Europace"},{"key":"732_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MCP.0000000000000748","volume":"27","author":"FS Leitao Filho","year":"2021","unstructured":"Leitao Filho FS, Choi L, Sin DD. Beta-blockers in chronic obstructive pulmonary disease: the good, the bad and the ugly. Curr Opin Pulm Med. 2021;27:125\u201331. https:\/\/doi.org\/10.1097\/MCP.0000000000000748.","journal-title":"Curr Opin Pulm Med"},{"key":"732_CR31","doi-asserted-by":"publisher","first-page":"CD003566","DOI":"10.1002\/14651858.CD003566.pub2","volume":"2005","author":"S Salpeter","year":"2005","unstructured":"Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;2005:CD003566. https:\/\/doi.org\/10.1002\/14651858.CD003566.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"732_CR32","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/jama.2024.8771","volume":"332","author":"G Devereux","year":"2024","unstructured":"Devereux G, Cotton S, Nath M, McMeekin N, Campbell K, et al. Bisoprolol in patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS randomized clinical trial. JAMA. 2024;332:462\u201370. https:\/\/doi.org\/10.1001\/jama.2024.8771.","journal-title":"JAMA"},{"key":"732_CR33","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1007\/s00380-019-01341-0","volume":"34","author":"WH Wang","year":"2019","unstructured":"Wang WH, Cheng CC, Mar GY, Wei KC, Huang WC, Liu CP. Improving outcomes in chronic obstructive pulmonary disease by taking beta-blockers after acute myocardial infarction: a nationwide observational study. Heart Vessels. 2019;34:1158\u201367. https:\/\/doi.org\/10.1007\/s00380-019-01341-0.","journal-title":"Heart Vessels"},{"key":"732_CR34","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.mayocp.2021.07.020","volume":"97","author":"CM Chung","year":"2022","unstructured":"Chung CM, Lin MS, Chang ST, Wang PC, Yang TY, Lin YS. Cardioselective versus nonselective \u03b2-blockers after myocardial infarction in adults with chronic obstructive pulmonary disease. Mayo Clin Proc. 2022;97:531\u201346. https:\/\/doi.org\/10.1016\/j.mayocp.2021.07.020.","journal-title":"Mayo Clin Proc"},{"key":"732_CR35","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1002\/ehf2.13489","volume":"8","author":"Y Kubota","year":"2021","unstructured":"Kubota Y, Tay WT, Teng TK, Asai K, Noda T, Kusano K, et al. Impact of beta-blocker use on the long-term outcomes of heart failure patients with chronic obstructive pulmonary disease. ESC Heart Fail. 2021;8:3791\u20139. https:\/\/doi.org\/10.1002\/ehf2.13489.","journal-title":"ESC Heart Fail."},{"key":"732_CR36","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.amjcard.2019.12.048","volume":"125","author":"M Sessa","year":"2020","unstructured":"Sessa M, Rasmussen DB, Jensen MT, Kragholm K, Torp-Pedersen C, Andersen M. Metoprolol versus carvedilol in patients with heart failure, chronic obstructive pulmonary disease, diabetes mellitus, and renal failure. Am J Cardiol. 2020;125:1069\u201376. https:\/\/doi.org\/10.1016\/j.amjcard.2019.12.048.","journal-title":"Am J Cardiol"},{"key":"732_CR37","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/eurjhf\/hfp066","volume":"11","author":"NM Hawkins","year":"2009","unstructured":"Hawkins NM, Macdonald MR, Petrie MC. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail. 2009;11:684\u201390. https:\/\/doi.org\/10.1093\/eurjhf\/hfp066.","journal-title":"Eur J Heart Fail"},{"key":"732_CR38","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/S0954-6111(11)70010-5","volume":"105","author":"M Lainscak","year":"2011","unstructured":"Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haehling S. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med. 2011;105:S44\u20139. https:\/\/doi.org\/10.1016\/S0954-6111(11)70010-5.","journal-title":"Respir Med"},{"key":"732_CR39","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.2147\/COPD.S141694","volume":"12","author":"KM Liao","year":"2017","unstructured":"Liao KM, Lin TY, Huang YW, Kuo CC, Chen CY. The evaluation of \u03b2-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. Int J Chron Obstruct Pulmon Dis. 2017;12:2573\u201381. https:\/\/doi.org\/10.2147\/COPD.S141694.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"732_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejim.2019.02.014","volume":"63","author":"C Andersson","year":"2019","unstructured":"Andersson C, Hansen PW, Steffensen IE, Andreasen C, Weeke PE, K\u00f8ber L, et al. Mortality associated with cardiovascular drugs in patients with chronic obstructive pulmonary disease and right-sided heart failure\u2014a Danish nationwide registry-based study. Eur J Intern Med. 2019;63:56\u201361. https:\/\/doi.org\/10.1016\/j.ejim.2019.02.014.","journal-title":"Eur J Intern Med"},{"key":"732_CR41","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.3390\/jcm10194378","volume":"10","author":"S Higuchi","year":"2021","unstructured":"Higuchi S, Kohno T, Kohsaka S, Shiraishi Y, Takei M, Goda A, et al. Different impact of beta-blockers on long-term mortality in heart failure patients with and without chronic obstructive pulmonary disease. J Clin Med. 2021;10:4378. https:\/\/doi.org\/10.3390\/jcm10194378.","journal-title":"J Clin Med"},{"key":"732_CR42","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/COPD.S174443","volume":"14","author":"M Rodr\u00edguez-Ma\u00f1ero","year":"2019","unstructured":"Rodr\u00edguez-Ma\u00f1ero M, L\u00f3pez-Pardo E, Cordero A, Ruano-Ravina A, Novo-Platas J, Pereira-V\u00e1zquez M, et al. A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population. Int J Chron Obstruct Pulmon Dis. 2019;14:371\u201380. https:\/\/doi.org\/10.2147\/COPD.S174443.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"732_CR43","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.3390\/jcm12093063","volume":"12","author":"D Vlachopoulou","year":"2023","unstructured":"Vlachopoulou D, Balomenakis C, Kartas A, Samaras A, Papazoglou AS, Moysidis DV, et al. Cardioselective versus non cardioselective beta-blockers and outcomes in patients with atrial fibrillation and chronic obstructive pulmonary disease. J Clin Med. 2023;12:3063. https:\/\/doi.org\/10.3390\/jcm12093063.","journal-title":"J Clin Med"},{"key":"732_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2023-001854","volume":"10","author":"SJ Lin","year":"2023","unstructured":"Lin SJ, Liao XM, Chen NY, Chang YC, Cheng CL. Beta-blockers reduce severe exacerbation in patients with mild chronic obstructive pulmonary disease with atrial fibrillation: a population-based cohort study. BMJ Open Respir Res. 2023;10: e001854. https:\/\/doi.org\/10.1136\/bmjresp-2023-001854.","journal-title":"BMJ Open Respir Res"},{"key":"732_CR45","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.amjmed.2004.07.043","volume":"117","author":"DH Au","year":"2004","unstructured":"Au DH, Bryson CL, Fan VS, Udris EM, Curtis JR, McDonell MB. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmomary disease. Am J Med. 2004;117:925\u201331. https:\/\/doi.org\/10.1016\/j.amjmed.2004.07.043.","journal-title":"Am J Med"},{"key":"732_CR46","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000076677","volume":"71","author":"M Cazzola","year":"2004","unstructured":"Cazzola M, Matera MG, Ruggeri P, Sanduzzi A, Spicuzza L, Vatrella A, et al. Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD. Respiration. 2004;71:159\u201364. https:\/\/doi.org\/10.1159\/000076677.","journal-title":"Respiration"},{"key":"732_CR47","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.amjcard.2012.10.041","volume":"111","author":"RJ Mentz","year":"2013","unstructured":"Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, O\u2019Connor CM. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol. 2013;111:582\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2012.10.041.","journal-title":"Am J Cardiol"},{"key":"732_CR48","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002427","volume":"95","author":"VYF Su","year":"2016","unstructured":"Su VYF, Chang YS, Hu YW, Hung MH, Ou SM, Lee FY, et al. Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease. Medicine (Baltimore). 2016;95: e2427. https:\/\/doi.org\/10.1097\/MD.0000000000002427.","journal-title":"Medicine (Baltimore)"},{"key":"732_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213187","volume":"14","author":"TH Su","year":"2019","unstructured":"Su TH, Chang SH, Kuo CF, Liu PH, Chan YL. \u03b2-blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide population-based observational study. PLoS ONE. 2019;14: e0213187. https:\/\/doi.org\/10.1371\/journal.pone.0213187.","journal-title":"PLoS ONE"},{"key":"732_CR50","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032785","volume":"13","author":"T Bucci","year":"2024","unstructured":"Bucci T, Romiti GF, Shantsila A, Teo WS, Park HW, Shimizu W, Asia-Pacific Heart Rhythm Society Atrial Fibrillation Registry Investigators, et al. Risk of death and cardiovascular events in Asian patients with atrial fibrillation and chronic obstructive pulmonary disease: a report from the prospective APHRS registry. J Am Heart Assoc. 2024;13: e032785. https:\/\/doi.org\/10.1161\/JAHA.123.032785.","journal-title":"J Am Heart Assoc"},{"key":"732_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113048","volume":"9","author":"Q Du","year":"2014","unstructured":"Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS ONE. 2014;9: e113048. https:\/\/doi.org\/10.1371\/journal.pone.0113048.","journal-title":"PLoS ONE"},{"key":"732_CR52","doi-asserted-by":"publisher","first-page":"00624","DOI":"10.1183\/23120541.00624-2020","volume":"7","author":"L Karimi","year":"2021","unstructured":"Karimi L, Lahousse L, Nocker PD, Stricker BH, Brusselle GG, Verhamme KMC. Effect of \u03b2-blockers on the risk of COPD exacerbations according to indication of use: the Rotterdam Study. ERJ Open Res. 2021;7:00624\u20132020. https:\/\/doi.org\/10.1183\/23120541.00624-2020.","journal-title":"ERJ Open Res."},{"key":"732_CR53","doi-asserted-by":"publisher","first-page":"e426","DOI":"10.1161\/CIR.0000000000000597","volume":"138","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138:e426\u201383. https:\/\/doi.org\/10.1161\/CIR.0000000000000597.","journal-title":"Circulation"},{"key":"732_CR54","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/s41598-019-47967-y","volume":"9","author":"M Sessa","year":"2019","unstructured":"Sessa M, Mascolo A, Rasmussen DB, Kragholm K, Jensen MT, Sportiello L, et al. Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study. Sci Rep. 2019;9:1146. https:\/\/doi.org\/10.1038\/s41598-019-47967-y.","journal-title":"Sci Rep"},{"key":"732_CR55","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178.","journal-title":"Eur Heart J"},{"key":"732_CR56","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. 2020 Gold Reports. 2020 global strategy for prevention, diagnosis and management of COPD. https:\/\/goldcopd.org\/gold-reports\/."},{"key":"732_CR57","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. ESH Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874\u20132071. https:\/\/doi.org\/10.1097\/HJH.0000000000003480.","journal-title":"J Hypertens"},{"key":"732_CR58","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","volume":"83","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC\/AHA\/ACCP\/HRS guidelines for the diagnosis and management of atrial fibrillation. J Am Coll Cardiol. 2024;83:109\u2013279. https:\/\/doi.org\/10.1016\/j.jacc.2023.08.017.","journal-title":"J Am Coll Cardiol"},{"key":"732_CR59","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/CIR.0b013e3182742c84","volume":"127","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:529\u201355. https:\/\/doi.org\/10.1161\/CIR.0b013e3182742c84.","journal-title":"Circulation"},{"key":"732_CR60","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/CIR.0000000000000134","volume":"130","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes. Circulation. 2014;130:e344-426. https:\/\/doi.org\/10.1161\/CIR.0000000000000134.","journal-title":"Circulation"},{"key":"732_CR61","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e263-421. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.012.","journal-title":"J Am Coll Cardiol"},{"key":"732_CR62","doi-asserted-by":"publisher","first-page":"66","DOI":"10.36628\/ijhf.2023.0011","volume":"5","author":"JC Youn","year":"2023","unstructured":"Youn JC, Kim D, Cho JY, Cho DH, Park SM, Jung MH, et al. Korean Society of Heart Failure guidelines for the management of heart failure: treatment. Int J Heart Fail. 2023;5:66\u201381. https:\/\/doi.org\/10.36628\/ijhf.2023.0011.","journal-title":"Int J Heart Fail."},{"key":"732_CR63","unstructured":"Department of Veterans Affairs. Department of Defense. VA\/DoD clinical practice guideline for the management of chronic obstructive pulmonary disease. 2021. https:\/\/www.healthquality.va.gov\/guidelines\/CD\/copd\/VADoDCOPDCPGFinal508.pdf."},{"key":"732_CR64","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1164\/rccm.202003-0625ST","volume":"201","author":"L Nici","year":"2020","unstructured":"Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd CM, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201:e56-69. https:\/\/doi.org\/10.1164\/rccm.202003-0625ST.","journal-title":"Am J Respir Crit Care Med"},{"key":"732_CR65","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1056\/NEJMra1805377","volume":"382","author":"SW Finks","year":"2020","unstructured":"Finks SW, Rumback MJ, Self TH. Treating hypertension in chronic obstructive pulmonary disease. N Engl J Med. 2020;382:353\u201363. https:\/\/doi.org\/10.1056\/NEJMra1805377.","journal-title":"N Engl J Med"},{"key":"732_CR66","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1093\/eurheartj\/ehaa793","volume":"41","author":"YL Yang","year":"2020","unstructured":"Yang YL, Xiang ZJ, Yang JH, Wang WJ, Xu ZC, Xiang RL. Association of \u03b2-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2020;41:4415\u201322. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa793.","journal-title":"Eur Heart J"},{"key":"732_CR67","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1378\/chest.11-1597","volume":"142","author":"M Wilchesky","year":"2012","unstructured":"Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest. 2012;142:305\u201311. https:\/\/doi.org\/10.1378\/chest.11-1597.","journal-title":"Chest"},{"key":"732_CR68","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1378\/chest.125.6.2309","volume":"125","author":"SR Salpeter","year":"2004","unstructured":"Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of \u03b2-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125:2309\u201321. https:\/\/doi.org\/10.1378\/chest.125.6.2309.","journal-title":"Chest"},{"key":"732_CR69","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","volume":"130","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071\u2013104. https:\/\/doi.org\/10.1161\/CIR.0000000000000040.","journal-title":"Circulation"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00732-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00732-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00732-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T11:46:29Z","timestamp":1757159189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00732-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["732"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00732-1","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,19]]},"assertion":[{"value":"10 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by funding from the Clinical Research Foundation of the Cardiovascular Society of the Chinese Medical Association and the 2022\u20132024 Guangdong Basic and Applied Basic Research Foundation to the authors\u2019 institutions,\u00a0Guangdong National Science Foundation (Nos. 2022A1515012161, 2022A1515010227, 2023A1515011794, 2024A1515010458) and by Merck\u00a0Serono Co.,\u00a0Ltd,\u00a0Beijing, China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Q.Y. is an employee of Merck Serono Co., Ltd, China (an affiliate of Merck KGaA Darmstadt, Germany). All other authors report no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No new data were generated or analyzed in support of this research.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors were involved with the conception and design of this manuscript, the drafting and critical revision of the manuscript, and final approval of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}